Anti-idiotype cancer vaccine 105AD7
Alternative Names: 105AD7; Onyvax-105Latest Information Update: 05 Aug 2015
Price :
$50 *
At a glance
- Originator University of Nottingham
- Developer Cancer Research Technology; National Cancer Institute (USA); Onyvax
- Class Cancer vaccines; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Colorectal cancer; Prostate cancer; Sarcoma
Most Recent Events
- 31 May 2007 A second-generation version of Onyvax 105 is being developed, which will enter preclinical development
- 05 Mar 2004 Phase-I clinical trials in Sarcoma in United Kingdom (Parenteral)
- 02 Jun 2000 Onyvax has been awarded a US patent covering 105AD7